Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046214 · ClinicalTrials.gov registry record · Phase 1
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01046214: Clinical Trial Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01046214 is a Phase 1 study that was terminated before completion, run by Teva Pharmaceuticals USA. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01046214, a Phase 1 study, was terminated before completion, sponsored by Teva Pharmaceuticals USA.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting conditions.
Interventions
- DRUG Bupropion HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01046214
The ClinicalTrials.gov registry entry for NCT01046214 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion HCl is the first listed.
NCT01046214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01046214 about?
NCT01046214 is a clinical study titled "Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions". The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting condition...
What is the current status of trial NCT01046214?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-01.
What interventions are being tested in trial NCT01046214?
The interventions under investigation include: Bupropion HCl (DRUG).
Who is sponsoring clinical trial NCT01046214?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.